Jun Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jun Zhou has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Kang Han
4 shared publicationsShengen Yi
3 shared publicationsShichao Yang
School of Biomedical Sciences, Hunan University
3 shared publicationsYu Zhao
3 shared publicationsGuofan Peng
2 shared publications- Guofan Peng
School of Biomedical Sciences, Hunan University
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (46)
Homeostatic control of stem cell activity during intestinal regeneration
Stem cells proliferate rapidly to maintain tissue turnover during regeneration, yet the mechanisms preventing hyperproliferation remain unclear. Here, we identified nuclear factor Y (NF-Y) as a transcriptional repressor that maintains intestinal stem cell (ISC) quiescence. NF-Y restricts ISC proliferation by occupying the promoters of epidermal growth factor receptor (EGFR) signaling components, including Egfr , Mkp3 , Raf , Ras , and pnt , through regulation dependent on the histone acetyltransferase Nejire (Nej)/p300. Loss of NF-Y enhances ISC proliferation and accelerates tumor progression. NF-Y acts with Nej to restrict Egfr expression and suppress hyperproliferation. Together, these results demonstrate that NF-Y, acting with Nej, serves as a key transcriptional repressive brake that restrains growth-signaling to control stem cell activity under homeostatic and disease conditions.
- 10 November 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (46)
Open AccessHomeostatic control of stem cell activity during intestinal regeneration
Stem cells proliferate rapidly to maintain tissue turnover during regeneration, yet the mechanisms preventing hyperproliferation remain unclear. Here, we identified nuclear factor Y (NF-Y) as a transcriptional repressor that maintains intestinal stem cell (ISC) quiescence. NF-Y restricts ISC proliferation by occupying the promoters of epidermal growth factor receptor (EGFR) signaling components, including Egfr , Mkp3 , Raf , Ras , and pnt , through regulation dependent on the histone acetyltransferase Nejire (Nej)/p300. Loss of NF-Y enhances ISC proliferation and accelerates tumor progression. NF-Y acts with Nej to restrict Egfr expression and suppress hyperproliferation. Together, these results demonstrate that NF-Y, acting with Nej, serves as a key transcriptional repressive brake that restrains growth-signaling to control stem cell activity under homeostatic and disease conditions.
- Open Access
- 20 October 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (11)
An engineered probiotic for diagnosis and mucosal healing in inflammatory bowel disease
- 20 October 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (11)
Open AccessAn engineered probiotic for diagnosis and mucosal healing in inflammatory bowel disease
- Open Access
- 18 August 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (8) , 102913
Synthetically engineered probiotic suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling
- 18 August 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (8) , 102913
Open AccessSynthetically engineered probiotic suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling
- 7 June 2026
- Published by Wiley in Angewandte Chemie
- p. e8271527
Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy
Targeting oncogene promoter G‐quadruplexes (G4s) is a compelling therapeutic strategy against human malignancies. However, clinical progress has been hindered by the lack of potent and structurally diverse G4‐targeting ligands. Herein, using parallel KRAS proximal promoter G4 ( KRAS ‐G4) as a model system, we screened an in‐house natural product library and identified dehydroevodiamine (DEE) as a novel G4 stabilizer. Although DEE showed only modest anticancer activity, structural analyses determined its predominant binding mode to KRAS ‐G4. Leveraging these structural insights, we rationally designed and synthesized 15 DEE analogues. Among them, compound 7i emerged as the lead candidate, demonstrating a 9‐fold higher binding affinity and up to 20‐fold improvement in antiproliferative activity over DEE. We further determined the high‐resolution NMR structure of the KRAS ‐G4– 7i complex, uncovering a distinct dual‐binding mode, featuring extensive π–π stacking interactions with outer G‐tetrads and specific hydrogen bonding within groove regions. Functional analysis showed 7i effectively suppressed transcription of several G4‐containing oncogenes, induced genome‐wide G4 formation, and triggered DNA damage in colorectal cancer cells. Moreover, 7i significantly inhibited the growth of patient‐derived colorectal tumor organoids. Overall, our findings establish a structural framework for rational design of parallel G4‐targeting ligands and emphasize an alternative G4‐based therapeutic strategy for KRAS ‐driven cancers.
- 7 June 2026
- Published by Wiley in Angewandte Chemie
- p. e8271527
Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy
Targeting oncogene promoter G‐quadruplexes (G4s) is a compelling therapeutic strategy against human malignancies. However, clinical progress has been hindered by the lack of potent and structurally diverse G4‐targeting ligands. Herein, using parallel KRAS proximal promoter G4 ( KRAS ‐G4) as a model system, we screened an in‐house natural product library and identified dehydroevodiamine (DEE) as a novel G4 stabilizer. Although DEE showed only modest anticancer activity, structural analyses determined its predominant binding mode to KRAS ‐G4. Leveraging these structural insights, we rationally designed and synthesized 15 DEE analogues. Among them, compound 7i emerged as the lead candidate, demonstrating a 9‐fold higher binding affinity and up to 20‐fold improvement in antiproliferative activity over DEE. We further determined the high‐resolution NMR structure of the KRAS ‐G4– 7i complex, uncovering a distinct dual‐binding mode, featuring extensive π–π stacking interactions with outer G‐tetrads and specific hydrogen bonding within groove regions. Functional analysis showed 7i effectively suppressed transcription of several G4‐containing oncogenes, induced genome‐wide G4 formation, and triggered DNA damage in colorectal cancer cells. Moreover, 7i significantly inhibited the growth of patient‐derived colorectal tumor organoids. Overall, our findings establish a structural framework for rational design of parallel G4‐targeting ligands and emphasize an alternative G4‐based therapeutic strategy for KRAS ‐driven cancers.
- 7 June 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (32) , e8271527
Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy
Targeting oncogene promoter G‐quadruplexes (G4s) is a compelling therapeutic strategy against human malignancies. However, clinical progress has been hindered by the lack of potent and structurally diverse G4‐targeting ligands. Herein, using parallel KRAS proximal promoter G4 ( KRAS ‐G4) as a model system, we screened an in‐house natural product library and identified dehydroevodiamine (DEE) as a novel G4 stabilizer. Although DEE showed only modest anticancer activity, structural analyses determined its predominant binding mode to KRAS ‐G4. Leveraging these structural insights, we rationally designed and synthesized 15 DEE analogues. Among them, compound 7i emerged as the lead candidate, demonstrating a 9‐fold higher binding affinity and up to 20‐fold improvement in antiproliferative activity over DEE. We further determined the high‐resolution NMR structure of the KRAS ‐G4– 7i complex, uncovering a distinct dual‐binding mode, featuring extensive π–π stacking interactions with outer G‐tetrads and specific hydrogen bonding within groove regions. Functional analysis showed 7i effectively suppressed transcription of several G4‐containing oncogenes, induced genome‐wide G4 formation, and triggered DNA damage in colorectal cancer cells. Moreover, 7i significantly inhibited the growth of patient‐derived colorectal tumor organoids. Overall, our findings establish a structural framework for rational design of parallel G4‐targeting ligands and emphasize an alternative G4‐based therapeutic strategy for KRAS ‐driven cancers.
- 7 June 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (32) , e8271527
Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy
Targeting oncogene promoter G‐quadruplexes (G4s) is a compelling therapeutic strategy against human malignancies. However, clinical progress has been hindered by the lack of potent and structurally diverse G4‐targeting ligands. Herein, using parallel KRAS proximal promoter G4 ( KRAS ‐G4) as a model system, we screened an in‐house natural product library and identified dehydroevodiamine (DEE) as a novel G4 stabilizer. Although DEE showed only modest anticancer activity, structural analyses determined its predominant binding mode to KRAS ‐G4. Leveraging these structural insights, we rationally designed and synthesized 15 DEE analogues. Among them, compound 7i emerged as the lead candidate, demonstrating a 9‐fold higher binding affinity and up to 20‐fold improvement in antiproliferative activity over DEE. We further determined the high‐resolution NMR structure of the KRAS ‐G4– 7i complex, uncovering a distinct dual‐binding mode, featuring extensive π–π stacking interactions with outer G‐tetrads and specific hydrogen bonding within groove regions. Functional analysis showed 7i effectively suppressed transcription of several G4‐containing oncogenes, induced genome‐wide G4 formation, and triggered DNA damage in colorectal cancer cells. Moreover, 7i significantly inhibited the growth of patient‐derived colorectal tumor organoids. Overall, our findings establish a structural framework for rational design of parallel G4‐targeting ligands and emphasize an alternative G4‐based therapeutic strategy for KRAS ‐driven cancers.
- Open Access
- 3 February 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (5) , 1270-1300
Toll signaling controls stem cell proliferation in intestinal regeneration and tumorigenesis
The Drosophila Toll/NF-κB pathway has been extensively studied for its roles in innate immunity and embryonic development. Nevertheless, the regulatory mechanisms underlying Spz/Toll signaling in non-immune contexts remain poorly understood. Here, we demonstrate a critical role for Toll in regulating intestinal stem cell activity through direct transcriptional control of PI3K and Akt in an insulin-independent manner. Time-series transcriptomic analysis of intestinal damage and repair responses reveals that the stress-responsive factor Jumu regulates Spz expression to activate Toll signaling. Disruption of the Jumu/Spz/Toll cascade or PI3K/Akt signaling impairs intestinal regeneration and suppresses tumor growth, and epistasis analysis confirms that PI3K/Akt functions downstream of Toll . Our findings elucidate an autocrine Spz/Toll-mediated mechanism that drives stem cell function via the PI3K/Akt pathway during tissue homeostasis and uncover a critical non-immune role of Toll signaling in both physiological and pathological contexts.
- 3 February 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (5) , 1270-1300
Open AccessToll signaling controls stem cell proliferation in intestinal regeneration and tumorigenesis
The Drosophila Toll/NF-κB pathway has been extensively studied for its roles in innate immunity and embryonic development. Nevertheless, the regulatory mechanisms underlying Spz/Toll signaling in non-immune contexts remain poorly understood. Here, we demonstrate a critical role for Toll in regulating intestinal stem cell activity through direct transcriptional control of PI3K and Akt in an insulin-independent manner. Time-series transcriptomic analysis of intestinal damage and repair responses reveals that the stress-responsive factor Jumu regulates Spz expression to activate Toll signaling. Disruption of the Jumu/Spz/Toll cascade or PI3K/Akt signaling impairs intestinal regeneration and suppresses tumor growth, and epistasis analysis confirms that PI3K/Akt functions downstream of Toll . Our findings elucidate an autocrine Spz/Toll-mediated mechanism that drives stem cell function via the PI3K/Akt pathway during tissue homeostasis and uncover a critical non-immune role of Toll signaling in both physiological and pathological contexts.
- Open Access
- 15 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Improved in vivo gene knockout with high specificity using multiplexed Cas12a sgRNAs
CRISPR nuclease-mediated gene knock-out is limited by suboptimal sgRNAs, inaccessible target sites, and undesired repair outcomes. Here, we present a Cas12a-based system in Drosophila that targets each gene with four sgRNAs to overcome these limitations. Multiplexed sgRNAs act through redundancy and synergism, frequently creating deletions between target sites and increasing the fraction of loss-of-function mutations. We show that multiplexed gene targeting is well tolerated and does not cause widespread proximity effects. To visualize CRISPR-nuclease activity in living animals, we developed a screening assay and used it to assess Cas12a activity across 33% of the Drosophila genome in combination with over 2000 sgRNAs. This revealed remarkably high on-target (>99%) and very low (<1%) off-target activity of multiplexed Cas12a sgRNA arrays. Quantitative side-by-side comparisons with current Cas9-based systems targeting over 100 genes in parallel demonstrate that multiplexed Cas12a gene targeting achieves superior performance and reveals phenotypes missed by established methods. The system described here provides a framework for reliable gene knock-out in multicellular systems.
- 15 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessImproved in vivo gene knockout with high specificity using multiplexed Cas12a sgRNAs
CRISPR nuclease-mediated gene knock-out is limited by suboptimal sgRNAs, inaccessible target sites, and undesired repair outcomes. Here, we present a Cas12a-based system in Drosophila that targets each gene with four sgRNAs to overcome these limitations. Multiplexed sgRNAs act through redundancy and synergism, frequently creating deletions between target sites and increasing the fraction of loss-of-function mutations. We show that multiplexed gene targeting is well tolerated and does not cause widespread proximity effects. To visualize CRISPR-nuclease activity in living animals, we developed a screening assay and used it to assess Cas12a activity across 33% of the Drosophila genome in combination with over 2000 sgRNAs. This revealed remarkably high on-target (>99%) and very low (<1%) off-target activity of multiplexed Cas12a sgRNA arrays. Quantitative side-by-side comparisons with current Cas9-based systems targeting over 100 genes in parallel demonstrate that multiplexed Cas12a gene targeting achieves superior performance and reveals phenotypes missed by established methods. The system described here provides a framework for reliable gene knock-out in multicellular systems.